2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory.  Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have attracted a lot of attention over the past two years thanks to their advances in the weight loss therapy market. Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering excellent returns for decades. Moreover, both healthcare giants appear likely to have plenty of growth fuel left in the tank, making them worth investing in for the long haul.Eli Lilly continues to break new ground. Its famous weight loss medicine, Zepbound (tirzepatide), just became the first to earn approval from the Food and Drug Administration as a treatment for moderate to severe obstructive sleep apnea in adults with obesity. Zepbound's sales were already growing fast. Its approval in this new indication should help increase the medicine's strong performance, and it's pursuing several other label expansions. Eli Lilly can also count on many years of sales growth from its diabetes medicine Mounjaro (a different brand for the same underlying compound, tirzepatide).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool